Form 4: Acurx Pharmaceuticals Director Receives Stock Options

Director Thomas L. Harrison was granted 2,150 stock options as part of the company's director compensation policy.

Summary

• Director Thomas L. Harrison received a grant of 2,150 stock options on April 20, 2026.
• The options have an exercise price of $2.36 per share.
• The options are set to vest on April 20, 2027, and expire on April 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Minor dilution of existing shares upon future exercise of options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $2.36 exercise price.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director compensation.

Management Comments

• The grant is issued pursuant to the Issuer's Director Compensation Policy.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to incentivize long-term oversight and strategic alignment without immediate cash outlays.

Comparison to Industry Standards

• The grant size and terms are consistent with standard director compensation packages for small-cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders due to the small number of options granted.

Next Steps

• Vesting of options on April 20, 2027.

Key Dates

Keywords

Acurx Pharmaceuticals, ACXP, Form 4, Director Compensation, Stock Options, Insider Transaction